Recent Company News

• 11:35 PM ET Mar 31, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (44 total)

• 11:10 PM ET Mar 31, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (32 total)

• 12:19 PM ET Mar 31, 2026
  

  Transcript Intelligence: Astellas Pharma R&D Day

• 09:13 PM ET Mar 30, 2026
  

  NICE recommends Astellas Pharma's Veoza to treat severe vasomotor symptoms associated with menopause

• 01:31 PM ET Mar 27, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 29-Mar

• 11:04 PM ET Mar 23, 2026
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 08:11 PM ET Mar 23, 2026
  

  Astellas Pharma upgraded to buy from hold at Jefferies (¥2478.0000, +117)

• 06:09 PM ET Mar 19, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:44 AM ET Mar 19, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 03:10 AM ET Mar 09, 2026
  

  Astellas Pharma, Hovon's phase 3 study in XOSPATA vs midostaurin-based treatment in patients with FLT3m+ AML did not meet its primary endpoint of overall survival (¥2370.0000, 0)